Identifying Treatment Regimens for Patients with Multiple Myeloma
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, advises on the best way to choose treatment regimens for patients with multiple myeloma. Since 9 different drugs have been approved after many phase III trials, a community physician may be overwhelmed by this surplus of options, Chari says.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, advises on the best way to choose treatment regimens for patients with multiple myeloma. Since 9 different drugs have been approved after many phase III trials, a community physician may be overwhelmed by this surplus of options, Chari says.
It is difficult to compare results across trials, Chari says. Each trial will have a different outcome, depending on patient factors, such as age, performance status, and comorbidities, disease factors, including burden of disease, molecular biology of the disease, or treatment issues like toxicity of the drug.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
